BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 16840409)

  • 1. Cytokines or their antagonists for the treatment of asthma.
    O'Byrne PM
    Chest; 2006 Jul; 130(1):244-50. PubMed ID: 16840409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reassessing the Th2 cytokine basis of asthma.
    O'Byrne PM; Inman MD; Adelroth E
    Trends Pharmacol Sci; 2004 May; 25(5):244-8. PubMed ID: 15120489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine antagonists for the treatment of asthma: progress to date.
    Antoniu SA
    BioDrugs; 2009; 23(4):241-51. PubMed ID: 19697966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agents against cytokine synthesis or receptors.
    Yamagata T; Ichinose M
    Eur J Pharmacol; 2006 Mar; 533(1-3):289-301. PubMed ID: 16457805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inflammatory cytokines (IL-4, IL-5 and IL-13)].
    Maeda S; Yanagihara Y
    Nihon Rinsho; 2001 Oct; 59(10):1894-9. PubMed ID: 11676128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel monoclonal treatments in severe asthma.
    Meteran H; Meteran H; Porsbjerg C; Backer V
    J Asthma; 2017 Dec; 54(10):991-1011. PubMed ID: 28287273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pitrakinra for asthma.
    Antoniu SA; Cojocaru I
    Expert Opin Biol Ther; 2010 Nov; 10(11):1609-15. PubMed ID: 20923253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine modulators as novel therapies for asthma.
    Barnes PJ
    Annu Rev Pharmacol Toxicol; 2002; 42():81-98. PubMed ID: 11807165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging interleukin receptor antagonists for the treatment of asthma.
    Al Efraij K; FitzGerald JM
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):275-283. PubMed ID: 28832218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flow cytometric detection of type 1 (IL-2, IFN-gamma) and type 2 (IL-4, IL-5) cytokines in T-helper and T-suppressor/cytotoxic cells in rheumatoid arthritis, allergic asthma and atopic dermatitis.
    Schuerwegh AJ; De Clerck LS; De Schutter L; Bridts CH; Verbruggen A; Stevens WJ
    Cytokine; 1999 Oct; 11(10):783-8. PubMed ID: 10525317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies for the treatment of refractory asthma.
    Hambly N; Nair P
    Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dupilumab : a new treatment for severe T2 high asthma].
    Louis R; Sabbe M; Bougard N; Frix AN; Schleich F
    Rev Med Liege; 2024 Apr; 79(4):255-259. PubMed ID: 38602214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New anti-asthma therapies: suppression of the effect of interleukin (IL)-4 and IL-5.
    Kips JC; Tournoy KG; Pauwels RA
    Eur Respir J; 2001 Mar; 17(3):499-506. PubMed ID: 11405532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.
    Bagnasco D; Ferrando M; Varricchi G; Passalacqua G; Canonica GW
    Int Arch Allergy Immunol; 2016; 170(2):122-31. PubMed ID: 27637004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Th2 cytokine antagonists: potential treatments for severe asthma.
    Hansbro PM; Scott GV; Essilfie AT; Kim RY; Starkey MR; Nguyen DH; Allen PD; Kaiko GE; Yang M; Horvat JC; Foster PS
    Expert Opin Investig Drugs; 2013 Jan; 22(1):49-69. PubMed ID: 23126660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual cytokines contributing to asthma pathophysiology: valid targets for asthma therapy?
    Chung KF
    Curr Opin Investig Drugs; 2003 Nov; 4(11):1320-6. PubMed ID: 14758771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease.
    Mitchell J; Dimov V; Townley RG
    Curr Opin Investig Drugs; 2010 May; 11(5):527-34. PubMed ID: 20419598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases.
    Nasert S; Millner M; Herz U; Lack G; Wahn U; Gelfand EW; Renz H
    Behring Inst Mitt; 1995 Jun; (96):118-30. PubMed ID: 7575347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial.
    De Boever EH; Ashman C; Cahn AP; Locantore NW; Overend P; Pouliquen IJ; Serone AP; Wright TJ; Jenkins MM; Panesar IS; Thiagarajah SS; Wenzel SE
    J Allergy Clin Immunol; 2014 Apr; 133(4):989-96. PubMed ID: 24582316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of histamine on Th1/Th2 cytokine balance.
    Packard KA; Khan MM
    Int Immunopharmacol; 2003 Jul; 3(7):909-20. PubMed ID: 12810348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.